Etrasimod was effective and well tolerated as an induction and maintenance therapy in patients with moderately to severely active ulcerative colitis Velsipity has a rapid onset, with symptom improvement starting as early as week 2 in some patients Etrasimod is a treatment option with a unique combination of attributes that might address the persistent unmet needs of patients with ulcerative colitis.
Manu Van Acker - The Ostendian
Both trials recruited adults with active, moderate to severe ulcerative colitis who were intolerant of, or had not responded to, other treatments
Velsipity (etrasimod) is a medication that treats ulcerative colitis (uc) in adults
The usual dose is 1 tablet by mouth once a day Velsipity (etrasimod) can cause side effects like headache and dizziness It also has a few serious risks, including infection, heart problems, and. Ulcerative colitis in adults (the “updated guidelines”)
Etrasimod, an s1p receptor modulator, is recommended for the induction of remission in patients with moderately to severely active uc and for continuation in the.
